Home  /  Resource Library  /  Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Study meansuring the response of lenalidomide combined with rituximab compared with chemoimmunotherapy for first line treatment of follicular lymphoma.